Klonoff, D.C., Buse, J.B., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., et al. (2008) Exenatide Effects on Diabetes, Obesity, Cardiovascular Risk Factors and Hepatic Biomarkers in Patients with Type 2 Diabetes Treated for at Least 3 Years. Current Medical Research and Opinion, 24, 275-286.

has been cited by the following article:

• TITLE: Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2

  AUTHORS: Alfonso López Ruiz, María Ángeles Núñez Sánchez, Noelia Victoria García-Talavera Espín, Amparo Meoro Avilés, Cristina del Peso Gilsanz, Ricardo Soriano Sánchez, María Teresa Gallego García, José Soriano Palao, María Dolores Ortuño, Sacramento Tomás Navarro, Collaborative Groups of the Diabetes and Obesity Unit of the Hospital Reina Sofía

  KEYWORDS: Type 2 Diabetes Mellitus; Exenatide; Cardiovascular Risk; Physical and Biochemical Parameters

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.4, April 23, 2014

  ABSTRACT: The purpose of this study was to analyze the effects of the treatment with Exenatide joint to insulin detemir. The study was carried out with obese patients with type 2 diabetes mellitus (DM2) and deficient control, despite intensive insulin therapy combined with oral antidiabetics. A longitudinal study was made with 15 patients controlled by the Endocrinology and Nutrition Section of the Reina Sofía University Hospital, Murcia. These patients were treated with Exenatide joint to insulin during 3, 6 and 12 months. Statistically meaningful differences (p